80 related articles for article (PubMed ID: 10918946)
1. Effects of beraprost and cilostazol and renal function on serum thrombomodulin levels in diabetic patients.
Hayakawa T; Shouzu A; Nishikawa M; Miyake Y; Shimizu H; Omoto S; Inada M
Arzneimittelforschung; 2000 Jun; 50(6):535-8. PubMed ID: 10918946
[TBL] [Abstract][Full Text] [Related]
2. Measurement of soluble thrombomodulin in sera from various clinical stages of diabetic nephropathy.
Rinno H; Kuramoto T; Iijima T; Yagame M; Tomino Y
J Clin Lab Anal; 1996; 10(3):119-24. PubMed ID: 8731497
[TBL] [Abstract][Full Text] [Related]
3. Plasma thrombomodulin: a marker for microvascular complications in diabetes mellitus.
Gabat S; Keller C; Kempe HP; Amiral J; Ziegler R; Ritz E; Bergis KH; Wahl P; Nawroth P
Vasa; 1996; 25(3):233-41. PubMed ID: 8795304
[TBL] [Abstract][Full Text] [Related]
4. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
Angiolillo DJ; Capranzano P; Goto S; Aslam M; Desai B; Charlton RK; Suzuki Y; Box LC; Shoemaker SB; Zenni MM; Guzman LA; Bass TA
Eur Heart J; 2008 Sep; 29(18):2202-11. PubMed ID: 18567918
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of elevation of serum and urinary concentrations of soluble thrombomodulin in diabetic patients: possible application as a marker for vascular endothelial injury.
Aso Y; Inukai T; Takemura Y
Metabolism; 1998 Mar; 47(3):362-5. PubMed ID: 9500578
[TBL] [Abstract][Full Text] [Related]
6. Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy.
Angiolillo DJ; Capranzano P; Ferreiro JL; Ueno M; Capodanno D; Dharmashankar K; Darlington A; Sumner S; Desai B; Charlton RK; Box LC; Zenni M; Guzman LA; Bass TA
Thromb Haemost; 2011 Aug; 106(2):253-62. PubMed ID: 21614414
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study.
Shinohara Y; Gotoh F; Tohgi H; Hirai S; Terashi A; Fukuuchi Y; Otomo E; Itoh E; Matsuda T; Sawada T; Yamaguchi T; Nishimaru K; Ohashi Y
Cerebrovasc Dis; 2008; 26(1):63-70. PubMed ID: 18511873
[TBL] [Abstract][Full Text] [Related]
8. [A study on inactive renin in the plasma of patients with diabetes mellitus].
Yoshida H
Hokkaido Igaku Zasshi; 1989 May; 64(3):232-42. PubMed ID: 2670725
[TBL] [Abstract][Full Text] [Related]
9. Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats.
Wang F; Li M; Cheng L; Zhang T; Hu J; Cao M; Zhao J; Guo R; Gao L; Zhang X
Life Sci; 2008 Dec; 83(25-26):828-35. PubMed ID: 18983856
[TBL] [Abstract][Full Text] [Related]
10. [Potential therapeutic approaches for prevention and treatment of diabetic nephropathy and neuropathy: evidences of cilostazol].
Rosa MP; Baroni GV; Portal VL
Arq Bras Endocrinol Metabol; 2007 Dec; 51(9):1528-32. PubMed ID: 18209897
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of livedo vasculitis with beraprost sodium: a possible mechanism of thrombomodulin upregulation.
Tsutsui K; Shirasaki F; Takata M; Takehara K
Dermatology; 1996; 192(2):120-4. PubMed ID: 8829492
[TBL] [Abstract][Full Text] [Related]
12. Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients.
Ohtake T; Sato M; Nakazawa R; Kondoh M; Miyaji T; Moriya H; Hidaka S; Kobayashi S
Ther Apher Dial; 2014 Feb; 18(1):1-8. PubMed ID: 24499078
[TBL] [Abstract][Full Text] [Related]
13. [Severe hypoglycemia in diabetics with impaired renal function].
Hasslacher C; Wittmann W
Dtsch Med Wochenschr; 2003 Feb; 128(6):253-6. PubMed ID: 12571792
[TBL] [Abstract][Full Text] [Related]
14. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.
Shimoike T; Inoguchi T; Umeda F; Nawata H; Kawano K; Ochi H
Metabolism; 2000 Aug; 49(8):1030-5. PubMed ID: 10954022
[TBL] [Abstract][Full Text] [Related]
15. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats.
Kalender B; Oztürk M; Tunçdemir M; Uysal O; Dagistanli FK; Yegenaga I; Erek E
Acta Histochem; 2002; 104(2):123-30. PubMed ID: 12086332
[TBL] [Abstract][Full Text] [Related]
16. Does pregnancy alter the rate of progression of diabetic nephropathy?
Reece EA; Winn HN; Hayslett JP; Coulehan J; Wan M; Hobbins JC
Am J Perinatol; 1990 Apr; 7(2):193-7. PubMed ID: 2331283
[TBL] [Abstract][Full Text] [Related]
17. Characterization of soluble thrombomodulin levels in patients with stage 3-5 chronic kidney disease.
Bao YS; Jia XB; Wang D; Liu RC; Zou CB; Na SP
Biomarkers; 2014 Jun; 19(4):275-80. PubMed ID: 24854597
[TBL] [Abstract][Full Text] [Related]
18. Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus.
Uchikawa T; Murakami T; Furukawa H
Arzneimittelforschung; 1992 Mar; 42(3):322-4. PubMed ID: 1497693
[TBL] [Abstract][Full Text] [Related]
19. Amelioration by beraprost sodium, a prostacyclin analogue, of established renal dysfunction in rat glomerulonephritis model.
Yamada M; Sasaki R; Sato N; Suzuki M; Tamura M; Matsushita T; Kurumatani H
Eur J Pharmacol; 2002 Aug; 449(1-2):167-76. PubMed ID: 12163121
[TBL] [Abstract][Full Text] [Related]
20. Amelioration of diabetic nephropathy in OLETF rats by prostaglandin I(2) analog, beraprost sodium.
Watanabe M; Nakashima H; Mochizuki S; Abe Y; Ishimura A; Ito K; Fukushima T; Miyake K; Ogahara S; Saito T
Am J Nephrol; 2009; 30(1):1-11. PubMed ID: 19158439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
